Treatment of Guillain-Barré syndrome and CIDP

Journal of the Peripheral Nervous System

Volumn 10, Issue 2, 2005, Pages 113-127

  Van Doorn, Pieter A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic inflammatory demyelinating poly(radiculo)neuropathy; CIDP; GBS; Guillain Barr syndrome; Intravenous immunoglobulin; Methylprednisolon; Miller Fisher syndrome; Plasma exchange; Steroids

Indexed keywords

AMANTADINE; AZATHIOPRINE; BETA INTERFERON; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SODIUM CHANNEL BLOCKING AGENT; STEROID;

ALGORITHM; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FATIGUE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT PLANNING;

ANIMALS; COMBINED MODALITY THERAPY; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MODELS, IMMUNOLOGICAL; PLASMA EXCHANGE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIALS;

EID: 22144494739     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1085-9489.2005.0010203.x     Document Type: Conference Paper

References (130)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (1991). Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41:617-618.
2. Ang CW, Jacobs BC, Laman JD (2004). The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 25:61-66.
3. Asbury AK (1981). Diagnostic considerations in Guillain-Barré syndrome. Ann Neurol 9:1-5.
4. Asbury AK, McKhann GM (1997). Changing views of Guillain-Barré syndrome. Ann Neurol 41:287-288.
5. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR (1989). Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 46:878-884.
6. Bechtold DA, Yue X, Evans RM, Davies M, Gregson NA, Smith KJ (2005). Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 128:18-28.
7. Benedetti L, Grandis M, Nobbio L, Beronio A, Ghiglione E, Manzino M, Primavera A, Mancardi G, Schenone A (2004). Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 29:748-749.
8. Berger AR, Bradley WG, Brannagan TH, Busis NA, Gros DP, Dalakas MC, Danon MJ, Donofrio P, Engel WK, England JD, Feldman EL, Freeman RL, Kinsella LJ, Lacomis D, Latov N, Menkes DL, Sander HW, Thomas FP, Triggs WJ, Windebank AJ, Wolfe GI; Neuropathy Association Medical Advisory Committee (2003). Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 8:282-284.
9. Brannagan TH III (2002). Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 59:S33-S40.
10. Brinkmeier H, Aulkemeyer P, Wollinsky KH, Rudel R (2000). An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med 6:808-811.
11. Buchwald B, Ahangari R, Weishaupt A, Toyka KV (2002). Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barrẽ syndrome. Ann Neurol 51:673-680.
12. Busby M, Donaghy M (2003). Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol 250:714-724.
13. Chin RL, Sherman WH, Sander HW, Hays AP, Latov N (2003). Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 210:19-21.
14. Creange A, Chazaud B, Plonquet A, Sharshar T, Poron F, Sonnet C, Raphael JC, Gherardi RK (2001). IFN-beta decreases adhesion and transmigration capacities of lymphocytes in Guillain-Barré syndrome. Neurology 57:1704-1706.
15. Czaplinski A, Steck AJ (2004). Immune mediated neuropathies - an update on therapeutic strategies. J Neurol 251:127-137.
16. Dalakas MC (2004). Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367-2375.
17. Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, Koeppen S, Vietorisz A (2001). A preliminary, randomised, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol 46:107-109.
18. Donofrio PD (2003). Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 28:273-292.
19. Dornonville de la Cour C, Andersen H, Stalberg E, Fuglsang-Frederiksen A, Jakobsen J (2005). Electrophysiological signs of permanent axonal loss in a follow-up study of patients with Guillain-Barré syndrome. Muscle Nerve 31:70-77.
20. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C (1986). Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461-465.
21. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC (1994). A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838-845.
22. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ (1982). Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11:136-141.
23. Dyck PJ, O'Brien P, Swanson C, Low P, Daube J (1985). Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 35:1173-1176.
24. Feasby TE, Hartung HP (2001). Drain the roots: a new treatment for Guillain-Barré syndrome? Neurology 57:753-754.
25. Garssen MP, Bussmann JB, Schmitz PI, Zandbergen A, Welter TG, Merkies IS, Stam HJ, van Doorn PA (2004). Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology 63:2393-2395.
26. Geleijns K, Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PA (2004a). The occurrence of Guillain-Barré syndrome within families. Neurology 63: 1747-1750.
27. Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA (2004b). Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients. J Neuroimmunol 150:132-138.
28. Geleijns K, Schreuder GM, Jacobs BC, Sintnicolaas K, van Koningsveld R, Meulstee J, Laman JD, van Doorn PA (2005). HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome. Neurology 64:44-49.
29. Godschalk PC, Heikema AP, Gilbert M, Komagamine T, Ang CW, Glerum J, Brochu D, Li J, Yuki N, Jacobs BC, van Belkum A, Endtz HP (2004). The crucial role of Campylobacter jejuni genes in anti-ganglioslde antibody induction in Guillain-Barré syndrome. J Clin Invest 114:1659-1665.
30. Govoni V, Granieri E (2001). Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol 14:605-613.
31. Green DM, Ropper AH (2001). Mild Guillain-Barré syndrome. Arch Neurol 58:1098-1101.
32. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, Asbury AK (1996a). Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 39:17-28.
33. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, Yang C, Tian M, Mishu B, Cornblath DR (1995). Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 118:577-595.
34. Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK (1996b). Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 25:33-51.
35. Guillain-Barré Syndrome Steroid Trial Group (1993). Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341:586-590.
36. Hadden RD, Hughes RA (2003). Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatry 74:ii9-ii14.
37. Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA (1999). Randomised trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53:57-61.
38. Hahn AF (1998). Guillain-Barré syndrome. Lancet 352:635-641.
39. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE (1996a). Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119:1055-1066.
40. Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996b). Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119:1067-1077.
41. Hodgkinson SJ, Pollard JD, McLeod JG (1990). Cyclosporm A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 53:327-330.
42. Holman R, Glas CA, Lindeboom R, Zwinderman AH, de Haan RJ (2004). Practical methods for dealing with 'not applicable' item responses in the AMC Linear Disability Score project. Health Qual Life Outcomes 2:29.
43. Hughes RA (1994). The spectrum of acquired demyelinating polyradiculoneuropathy. Acta Neurol Belg 94:128-132.
44. Hughes RA (2001). Chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:281-282.
45. Hughes RA (2003). Management of chronic inflammatory demyelinating polyradiculoneuropathy. Drugs 63:275-287.
46. Hughes RA (2004). Treatment of Guillain-Barré syndrome with corticosteroids: lack of benefit? Lancet 363:181-182.
47. Hughes R, Bensa S, Van den Willison HBP, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A (2001). Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195-201.
48. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978). Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750-753.
49. Hughes RA, van der Meché FG (2000). Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev CD001446.
50. Hughes RA, Raphael JC, Swan AV, Doorn PA (2004). Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev CD002063.
51. Hughes R, Swan A, Doorn P (2003a). Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev CD003280.
52. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC; Quality Standards Subcommittee of the American Academy of Neurology (2003b). Practice parameter: immunotherapy for Guillain-Barré syndrome. Neurology 61:736-740.
53. Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ (2003). Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126: 2220-2234.
54. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA (1998). The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51:1110-1115.
55. Kabore R, Magy L, Boukhris S, Mabrouk T, Lacoste M, Vallat JM (2004). [Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome]. Rev Neurol (Paris) 160:821-823.
56. Katz JS, Saperstein DS (2001). Asymmetric acquired demyelinating polyneuropathies: MMN and MADSAM. Curr Treat Options Neurol 3:119-125.
57. Katz JS, Saperstein DS (2003). Chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 5:357-364.
58. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ (2000). Distal acquired demyelinating symmetric neuropathy. Neurology 54:615-620.
59. Kazatchkine MD, Kaveri SV (2001). Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747-755.
60. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP (2004). Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131-156.
61. Kissel JT (2003). The treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Semin Neurol 23:169-180.
62. Köller H, Kieseirer BC, Jander S, Hartung HP (2005). Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343-1356.
63. Koski CL (2002). Therapy of CIDP and related immune-mediated neuropathies. Neurology 59:S22-S27.
64. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF (2001). Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 58:893-898.
65. Magda P, Latov N, Brannagan TH III, Weimer LH, Chin RL, Sander HW (2003). Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 60:1755-1759.
66. Magira EE, Papaloakim M, Nachamkin I, Asbury AK, Li CY, Ho TW, Griffin JW, McKhann GM, Monos DS (2003). Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol 170:3074-3080.
67. Mastaglia FL (2005). Neuromuscular disorders: molecular and therapeutic insights. Lancet Neurol 4:6-7.
68. Matsuda M, Hoshi K, Gono T, Morita H, Ikeda S (2004). Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 224:29-35.
69. Matsuse D, Ochi H, Tashiro K, Nomura T, Murai H, Taniwaki T, Kira J (2005). Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during Interferon beta-1 therapy in a patient with childhood-onset multiple sclerosis. Intern Med 44:68-72.
70. McCombe PA, Pollard JD, McLeod JG (1987). Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 110: 1617-1630.
71. McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas MC, Illa I, Kilindireas C, Nobile-Orazio E, Swan A, Van den Bergh P, Willison HJ; The INCAT Study Group (2003). Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 10:687-694.
72. Mehndiratta MM, Hughes RA (2001). Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev CD002062.
73. Mehndiratta MM, Hughes RA, Agarwal P (2004). Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev CD003906.
74. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ (2001). Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445-449.
75. Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA (2000). Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 54:943-949.
76. Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA (2003). Comparison between impairment and disability scales in immune-mediated polyneuropathies. Muscle Nerve 28: 93-100.
77. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA (2002a). Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72:596-601.
78. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA (2002b). Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 25: 370-377.
79. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA (1999). Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 53:1648-1654.
80. Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, Akiguchi I (2002). New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 25:280-282.
81. Mori K, Hattori N, Sugiura M, Koike H, Misu K, Ichimura M, Hirayama M, Sobue G (2002). Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 58:979-982.
82. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T (2001). Clinical features and prognosis of Miller Fisher syndrome. Neurology 56:1104-1106.
83. Mowzoon N, Sussman A, Bradley WG (2001). Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 185:119-122.
84. Nishimoto Y, Koga M, Kamijo M, Hirata K, Yuki N (2004). Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology 62:1939-1944.
85. Odaka M, Yuki N, Hirata K (2003). Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome. J Neurol 250:913-916.
86. Oh SJ, Kurokawa K, de Almeida DF, Ryan HF Jr, Claussen GC (2003). Subacute inflammatory demyelinating polyneuropathy. Neurology 61:1507-1512.
87. Pirko I, Kuntz NL, Patterson M, Keegan BM, Weinshenker BG, Rodriguez M (2003). Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination. Neurology 60:1697-1699.
88. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1997). Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349:225-230.
89. Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, Willison HJ, Winer JB, Hughes RA (2003). A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 61:1282-1284.
90. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC (2001). Intravenous immune globulins in patients with Guillain-Barré sndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71: 235-238.
91. Raphael JC, Chevret S, Hughes RA, Annane D (2002). Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev CD001798.
92. Ropper AH (2003). Current treatments for CIDP. Neurology 60:S16-S22.
93. Ruts L, Jacobs BC, van Koringsveld R, van Doorn PA (2003). Pain syndromes in Guillain-Barré syndrome, indidence and response to methylprednisolone. J Peripher Nerv Syst 8:55.
94. Said G (2002). Chronic inflammatory demyelinative polyneuropathy. J Neurol 249:245-253.
95. Sander HW, Latov N (2003). Research criteria for defining patients with CIDP. Neurology 60:S8-S15.
96. Sheikh KA, Griffin JW (2001). Variants of the Guillain Barré syndrome: progress toward fulfilling "Koch's postulates." Ann Neurol 49:694-696.
97. Susuki K, Johkura K, Yuki N, Hasegawa O, Kuroiwa Y (2001). Rapid resolution of nerve conduction blocks after plasmapheresis in Guillain-Barré syndrome associated with anti-GM1betaIgG antibody. J Neurol 248:148-150.
98. Susuki K, Yuki N (2004). Effect of methylprednisolone in patients with Guillain-Barré syndrome. Lancet 363:1236-1237.
99. The Dutch Guillain-Barré Study Group (1994). Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749-752.
100. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome (1987). Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 22:753-761.
101. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome (1997). Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 41:298-306.
102. The Guillain-Barré Syndrome Study Group (1985). Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35:1096-1104.
103. Toyka KV, Gold R (2003). The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 60:S2-S7.
104. Umapathi T, Hughes R (2002). Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 9:683-685.
105. Vallat JM, Hahn AF, Leger JM, Cros DP, Magy L, Tabaraud F, Bouche P, Preux PM (2003). Interferon beta-1a as an investigational treatment for CIDP. Neurology 60:S23-S28.
106. Van den Bergh PY, Pieret F (2004). Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 29:565-574.
107. van der Meché FG, Schmitz PI (1992). A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 326:1123-1129.
108. van der Meché FG, van Doorn PA, Meulstee J, Jennekens FG (2001). Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 45:133-139.
109. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M (1990). High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209-212.
110. van Doorn PA, Dippel DWJ, van Burken MMG, Sherrenburg A, Scrutjens M, Vermeulen M (2003). J Peripher Nerv Syst 8:70-71.
111. van Doorn PA, Garssen MP (2002). Treatment of immune neuropathies. Curr Opin Neurol 15:623-631.
112. van Doorn PA, Ruts L (2004). Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol 17: 607-613.
113. van Doorn PA, van Koningsveld R (2004). Immunotherapy for Guillain-Barré syndrome. Lancet Neurol 3:84.
114. van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF (1991). Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 48:217-220.
115. van Koningsveld R, Schmitz PI, Ang CW, Groen J, Osterhaus AD, van der Meché FG, van Doorn PA (2002). Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurology 58:610-614.
116. van Koningsveld R, Schmitz PI, van der Meché FG, Visser LH, Meulstee J, van Doorn PA (2004). Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363:192-196.
117. van Koningsveld R, van Doorn PA, Schmitz PI, Ang CW, van der Meché FG (2000). Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 54:620-625.
118. van Koningsveld R, van Doorn PA, Schmitz PI, van der Meché FG (2001). Changes in referral pattern and its effect on outcome in patients with Guillain-Barré syndrome. Neurology 56: 564-566.
119. van Schaik IN, Winer JB, de Haan R, Vermeulen M (2002a). Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev CD001797.
120. van Schaik IN, Winer JB, de Haan R, Vermeulen M (2002b). Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 1:491-498.
121. van Sorge NM, Van den Berg LH, Geleijns K, van Strijp JA, Jacobs BC, van Doorn PA, Wokke JH, van de Winkel JG, Leusen JH, van der Pol WL (2003a). Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Ann Neurol 53:570-579.
122. van Sorge NM, van der Pol WL, van de Winkel JG (2003b). FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61:189-202.
123. Venance SL, Koopman WJ, Hahn AF (2003). Treatment approaches and long-term outcome in a Canadian cohort (1972-2002) with chronic inflammatory demyelinating polyneuropathy (CIDP). J Peripher Nerv Syst 8:71.
124. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF (1993). Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36-39.
125. Walk D, Li LY, Parry GJ, Day JW (2004). Rapid resolution of quadriplegic CIDP by combined plasmapheresis and IVIg. Neurology 62:155-156.
126. Willison HJ, Yuki N (2002). Peripheral neuropathies and antiglycolipid antibodies. Brain 125:2591-2625.
127. Wilmshurst JM, Thomas NH, Robinson RO, Bingham JB, Pohl KR (2001). Lower limb and back pain in Guillain-Barré syndrome and associated contrast enhancement in MRI of the cauda equina. Acta Paediatr 90:691-694.
128. Yuki N (2001). Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis 1: 29-37.
129. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M (2004). Carbohydrate mimicry between human ganglioside GM 1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA 101: 11404-11409.
130. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K (2001). Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49:712-720.